COVID-19 Drug Development: Clinical Trial Design Considerations

An article reviewing translational science principles for conducting clinical trials during the COVID-19 pandemic. It evaluates recent trials for drug candidates including hydroxychloroquine, remdesivir, lopinavir-ritonavir, fapiravir, and tocilizumab. The author is Jun Shi and the license is Open Access.

Use Cases

• Review clinical trial design strategies based on translational science principles mentioned in the description
• Evaluate recent clinical trial outcomes based on the analysis of specific drug candidates like hydroxychloroquine and remdesivir
• Inform pandemic response planning based on principles for conducting clinical trials during a crisis

Strengths

• Focuses on five specific drug candidates: hydroxychloroquine, remdesivir, lopinavir-ritonavir, fapiravir, and tocilizumab.
• Applies translational science principles specifically to the context of a pandemic.

Limitations

• The dataset is described as an article; its format and structure as a dataset are unclear.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count and sample data are unknown, which may limit suitability assessment.

Provenance

Source

paperswithcode

Time Range

COVID-19 pandemic period